<DOC>
	<DOCNO>NCT02825797</DOCNO>
	<brief_summary>This phase 1b clinical trial evaluate safety , pharmacokinetics antiretroviral effect combination two anti-human immunodeficiency virus ( HIV ) broadly neutralize antibody , 3BNC117 10-1074 , administer intravenously HIV-infected individual . This study intend support development combination 3BNC117 10-1074 mAbs use treatment HIV-1 infection .</brief_summary>
	<brief_title>3BNC117 10-1074 HIV-infected Individuals</brief_title>
	<detailed_description>The propose study Phase 1b clinical trial evaluate safety , pharmacokinetics antiretroviral effect combination two anti-HIV broadly neutralizing antibody , 3BNC117 10-1074 , administer intravenously HIV-infected individual . The study include 5 study group . Study participant administer one three intravenous infusion 3BNC117 10-1074 , mAb dose 10 30 mg/kg : Single dose group : Group 1A ( n=6 ) - HIV-infected individual , antiretroviral therapy ( ART ) HIV-1 RNA &lt; 20 copies/ml randomize 2:1 ratio receive one intravenous infusion 3BNC117 one infusion 10-1074 , dose 10 mg/kg ( n=4 ) , OR placebo ( sterile saline ; n=2 ) , day 0 . Group 1B ( n=6 ) - HIV-infected individual , ART HIV-1 RNA &lt; 20 copies/ml randomize 2:1 ratio receive one intravenous infusion 3BNC117 one infusion 10-1074 , dose 30 mg/kg ( n=4 ) , OR placebo ( sterile saline ; n=2 ) , day 0 . Participants investigator blind study assignment group 1A 1B . Group 1C ( n=4 ) - HIV-infected individual , ART administer one infusion 3BNC117 one infusion 10-1074 , dose 30 mg/kg , day 0 . Three dos group : Group 2 ( n=15 ) - HIV-infected individual , ART administer three infusion 3BNC117 three infusion 10-1074 , dose 30 mg/kg , day 0 , 21 ( week 3 ) 42 ( week 6 ) . Participants enrol Group 2 discontinue antiretroviral ( ART ) regimen day 2 . Group 3 ( n=6 ) - HIV-infected individual , ART administer three infusion 3BNC117 three infusion 10-1074 , dose 30 mg/kg day 0 , 14 ( week 2 ) 28 ( week 4 ) . Following 3BNC117 10-1074 infusion , study participant return safety assessment multiple time point . Blood sample collect safety test week 1 , 2 , 4 follow mAb infusion , bi-monthly monthly end study follow . Serum sample PK ( pharmacokinetic ) measurement collect start first mAb infusion . Peak PK sample 3BNC117 occur follow completion 3BNC117 infusion prior start 10-1074 infusion . Peak PK sample 10-1074 occur follow completion 10-1074 infusion . Additional sample PK assessment collect multiple time point study follow . Samples also collect measurement HIV-1 plasma RNA level 3BNC117 10-1074 infusion ( screen , pre-infusion day 0 ) , follow visit Groups 1A , 1B 2 , weekly ATI period later time point Group 2 . All participant follow 24 week last 3BNC117 10-1074 infusion .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All group : Age 18 65 . HIV1 infection confirm two independent laboratory assay . If sexually active male female , participate sexual activity could lead pregnancy , agree use two effective method contraception ( i.e . condom spermicide , diaphragm spermicide , hormoneeluting intrauterine device ( IUD ) , hormonebased contraceptive condom ) study duration . Groups 1A 1B : HIVinfected volunteer ART HIV1 plasma RNA level &lt; 20 copies/ml . Current CD4 cell count &gt; 300 cells/μl . Groups 1C 3 : HIVinfected volunteer ART detectable HIV1 plasma RNA level &lt; 100,000 copies/ml standard assay . Current CD4 cell count &gt; 300 cells/μl . Group 2 : On antiretroviral therapy minimum 24 month , plasma HIV1 RNA level &lt; 50 copies/ml least 18 month , &lt; 20 copies/ml screening . Note : single viral load measurement &gt; 50 &lt; 500 copies/ml time period allow . Current CD4+ T cell count &gt; 500 cells/μl . CD4 cell count nadir &gt; 200 cells/μl . If NNRTIbased regimen willing switch dolutegravirbased regimen 4 week prior discontinue ART . Have history AIDSdefining illness within 3 year prior enrollment . History systemic corticosteroid , immunosuppressive anticancer , medication consider significant trial physician within last 6 month . Any clinically significant acute chronic medical condition ( autoimmune disease coronary artery disease ) , HIV infection , opinion investigator would preclude participation . Hepatitis B C infection indicate presence Hepatitis B surface antigen ( HBsAg ) hepatitis C virus RNA ( HCVRNA ) blood . History resistance 2 class antiretroviral medication know resistance dolutegravir participant nonnucleoside reversetranscriptase inhibitor ( NNRTI ) , would switch regimen prior ATI ( Group 2 ) . Laboratory abnormality parameter list : Absolute neutrophil count ≤ 1,000 cells/l Hemoglobin ≤ 10 gm/dL Platelet count ≤ 100,000 cells/l Alanine Aminotransferase ( AST ) ≥ 1.5 x ULN Aspartate Aminotransferase ( AST ) ≥ 1.5 x ULN Alkaline phosphatase ≥ 1.5 x ULN Total bilirubin &gt; 1.0 ULN eGFR &lt; 60 mL/min/1.73m2 Pregnancy lactation ; Any vaccination within 14 day prior 3BNC117 101074 administration ; Subjects know hypersensitivity constituent investigational product ; Receipt therapeutic HIV vaccine monoclonal antibody therapy kind past ; Participation another clinical study investigational product currently within past 12 week , expect participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Broadly neutralize antibody</keyword>
	<keyword>3BNC117</keyword>
	<keyword>10-1074</keyword>
</DOC>